Looking Ahead: Durability, Biomarkers, and the Future of CD19-Targeted Therapy in gMG

Despite recent advances in biologic therapies for generalized myasthenia gravis, important questions remain regarding long-term disease control, patient selection, and optimal treatment strategies. As more data emerge from clinical trials and real-world experience, the focus is shifting toward refining how these therapies are used in practice and identifying which patients stand to benefit most.

At the 2026 AAN Annual Meeting in Chicago, Richard Nowak, MD, MS, associate professor of neurology at Yale School of Medicine, spoke with NeurologyLive® about the evolving role of inebilizumab following results from the phase 3 MINT trial. With 26-week and 52-week findings now available, along with an ongoing open-label extension, the conversation highlights how additional data will help shape long-term treatment strategies and inform clinical decision-making.

In this final episode, Nowak explores key unanswered questions, including durability of response beyond one year, the development of predictive biomarkers, and how real-world data may further define the role of CD19-targeted therapy. He also discusses the need to evaluate broader patient populations, including seronegative and ocular myasthenia gravis, as the field continues to evolve.